Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary cutaneous B-cell lymphomas. Current concepts. I.

Marco Santucci1, Nicola Pimpinelli

  • 1Department of Human Pathology and Oncology, University of Florence Medical School, Florence, Italy. marco.santucci@unifi.it <marco.santucci@unifi.it>

Haematologica
|November 9, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Round robin on structure analysis from 3D electron diffraction data.

IUCrJ·2026
Same author

T2-Reg: a regional web registry on Th2-mediated diseases.

Italian journal of dermatology and venereology·2026
Same author

Evaluation of the reproducibility and crystal tracking precision of TEM goniometers in tomography experiments.

Ultramicroscopy·2026
Same author

Therapeutic Modulation Of Peripheral Blood Cells And Inflammatory Indices During 52 Weeks Of Risankizumab In Responder Patients With Moderate-to-Severe Psoriasis: Results From A Multicenter Prospective Study.

Dermatology practical & conceptual·2025
Same author

Effectiveness and safety of baricitinib in severe alopecia areata: 48-week results.

Journal of the European Academy of Dermatology and Venereology : JEADV·2025
Same author

Quality and duration of responses with mogamulizumab in cutaneous T-cell lymphomas: Insights into long-lasting outcomes.

British journal of haematology·2025

Primary cutaneous B-cell lymphoma (pCBCL) is a distinct skin cancer. Most subtypes, like follicular center cell and marginal zone lymphomas, have excellent prognoses with radiation therapy being the preferred treatment.

Area of Science:

  • Dermatology
  • Oncology
  • Hematology

Background:

  • Primary cutaneous B-cell lymphoma (pCBCL) is a distinct clinicopathologic entity.
  • It must be differentiated from secondary skin involvement by non-Hodgkin's lymphomas and cutaneous pseudolymphomas.
  • pCBCL originates in the skin with no evidence of extracutaneous disease at presentation.

Purpose of the Study:

  • To provide a concise summary of the diagnosis, course, and treatment of pCBCL.
  • To clarify classification, treatment, and prognosis for pCBCL patients.
  • To highlight the European Organization for Research and Treatment of Cancer (EORTC) classification for improved patient management.

Main Methods:

  • Utilizing improved immunophenotyping and immunogenotyping for diagnosis.

Related Experiment Videos

  • Applying the EORTC classification based on clinical behavior and histopathologic findings.
  • Reviewing clinical data on diagnosis, staging, and treatment outcomes.

    • Main Results:

    • Follicular center cell lymphoma and marginal zone B-cell lymphoma are common pCBCL subtypes with excellent prognoses (>95% 5-year survival).
    • Local cutaneous recurrences occur in ~25% of patients, but dissemination is rare.
    • Large B-cell lymphoma of the leg has a poorer prognosis (~60% 5-year survival).

    Conclusions:

    • pCBCL generally shows high responsiveness to radiation therapy, making it the treatment of choice.
    • Polychemotherapy is reserved for specific cases: multi-site involvement, refractory disease, or extracutaneous spread.
    • The EORTC classification aids in better management and understanding of pCBCL subtypes.